Zytiga (abiraterone) is used to treat individuals suffering from prostate cancer. The drug is part of the CYP17 inhibitors drug class. Prostate cancer begins in the male prostate gland and is the second most common cancer in men.
Drug Name: Zytiga Generic name: Abiraterone acetate
The active ingredients of Zytiga are:
abiraterone acetate Drug Class:
Cytochrome P450 17A1 Inhibitors [MoA] ,
Cytochrome P450 17A1 Inhibitor [EPC] ,
Cytochrome P450 2D6 Inhibitors [MoA] ,
Cytochrome P450 2C8 Inhibitors [MoA]
Zytiga is prescribed to an individual suffering from advanced prostate cancer. Prostate cancer symptoms include trouble with urination, blood in the urine, erectile dysfunction, and others.
Prostate cancer latches on to androgens, which are produced by the CYP17 enzyme. Lowering the androgens can prevent prostate cancer from spreading. Zytiga is a CYP17 inhibitor that helps to block the enzyme and lowers the androgen levels in the individual.
Below you will find the different uses for Zytiga:
The availble dosage of Zytiga are:
500mg/1 - Tablet, film coated:
Zytiga Side Effects
While taking Zytiga, individuals may experience different side effects. Note, not all side effects are listed here. If you experience any severe side effects, consult with your doctor immediately or seek medical attention.
More Common Zytiga Side Effects:
Consult with your doctor if you experience any of the following side effects:
Loss of appetite
Redness of face, neck, arms
If combined with other medications, individuals may experience serious side effects. Consult with your doctor before taking Zytiga. Below is a list of drugs that have been known to interact with Zytiga. Note, this list does not include all possible drug interactions.
The free Pharmacy Coupons Zytiga Coupon and Discount Card can save you up to 75%** off your prescription prices. All you have to do is print the coupon and bring it to the pharmacy to receive the benefits of our drug discount program. This coupon is not insurance and is not valid in combination with any government-sponsored drug plans.